Bulletin of Experimental Biology and Medicine

, Volume 88, Issue 4, pp 1162–1166 | Cite as

Modification of the toxic and antitumor properties of ftorafur by action aimed at nonspecific microsomal oxidases

  • G. A. Belitskii
  • V. M. Bukhman
  • I. A. Konopleva
Oncology
  • 13 Downloads

Abstract

Phenobarbital and methylcholanthrene, inducers of nonspecific microsomal oxidases, inhibit the development of neurotoxic shock produced in mice by large doses of ftorafur, but they increase the mortality among the animals on the 4th–8th days after administration of the compound. Inhibitor SKF525 A has the opposite action on both types of toxic manifestations. The antitumor effect of ftorafur, determined on the basis of the decrease in weight of the spleen in mice with Rauscher leukemia, is greatly enhanced by preliminary administration of phenobarbital, alone or together with methylcholanthrene, to mice.

Key Words

ftorafur nonspecific microsomal oxidases 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literature Cited

  1. 1.
    N. G. Blokhina, A. M. Garin, and É. K. Voznyi, in: Experimental and Clinical Pharmacotherapy, No. 7 [in Russian], Riga (1977), pp. 224–233.Google Scholar
  2. 2.
    B. T. Gabridzhanyan, I. Klein, R. J. Johnson, et al., in: Experimental and Clinical Pharmacotherapy, No. 7 [in Russian], Riga (1977), pp. 116–123.Google Scholar
  3. 3.
    B. T. Gabridzhanyan, I. Klein, M. Lang, et al., in: Experimental and Clinical Pharmacotherapy, No. 7, [in Russian], Riga (1977), pp. 23–43.Google Scholar
  4. 4.
    S. K. Germane and A. A. Kamenis, in: Experimental and Clinical Pharmacotherapy, No. 7, [in Russian], Riga (1977), pp. 135–139.Google Scholar
  5. 5.
    S. A. Giller, R. A. Zhuk, and M. Yu. Lidak, in: Experimental and Clinical Pharmacotherapy, No. 7 [in Russian], Riga (1977), pp. 9–18.Google Scholar
  6. 6.
    A. P. Gilev, Kh. B. Khagi, D. V. Meirene, et al., in: Experimental and Clinical Pharmacotherapy, No. 7 [in Russian], Riga (1977), pp. 77–92.Google Scholar
  7. 7.
    A. A. Zindermane and I. M. Kravchenko, in: Experimental and Clinical Pharmacotherapy, No. 7 [in Russian], Riga (1977), pp. 19–22.Google Scholar
  8. 8.
    I. M. Kravchenko, A. Zh. Dauvarte, A. M. Zilbere, et al., in: Experimental and Clinical Pharmacotherapy, No. 7 [in Russian], Riga (1977), pp. 100–115.Google Scholar
  9. 9.
    D. V. Meirene, É. L. Urbanovich, T. N. Sniedze, et al., Byull. Éksp. Biol. Med., No. 2, 162 (1977).Google Scholar
  10. 10.
    M. A. Chirigos, Cancer Res.,24, 1035 (1964).Google Scholar
  11. 11.
    J. R. Gillette, Metabolism,20, 215 (1971).Google Scholar
  12. 12.
    A. Y. H. Lu, R. Kuntzman, S. West, et al., Biochem. Biophys. Res. Commun.,42, 1200 (1971).Google Scholar
  13. 13.
    L. A. Rogers and G. R. Fouts, J. Pharmacol. Exp. Ther.,146, 286 (1964).Google Scholar
  14. 14.
    P. Sims, Biochem. Pharmacol.,19, 2261 (1970).Google Scholar
  15. 15.
    A. T. Wu, J. L. Au, and W. Sadee, Cancer Res.,38, 210 (1978).Google Scholar

Copyright information

© Plenum Publishing Corporation 1980

Authors and Affiliations

  • G. A. Belitskii
  • V. M. Bukhman
  • I. A. Konopleva

There are no affiliations available

Personalised recommendations